Emtricitabine for adults with lamivudine‐resistant chronic hepatitis B virus infection
Referencias
Additional references
Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology (Baltimore, Md.) 1998;27(6):1670‐7.
Andreone P, Gramenzi A, Cursaro C, Biselli M, Cammà C, Trevisani F, et al. High risk of hepatocellular carcinoma in anti‐HBe positive liver cirrhosis patients developing lamivudine resistance. Journal of Viral Hepatitis 2004;11(5):439‐42.
Ang EL, Banez V, Flores H, Estanislao N, Velasquez M. Entecavir in lamivudine‐refractory chronic hepatitis B infection: a meta‐analysis. Hepatology International 2010;4(1):143.
Liaw YF, Kao JH, Piratvisuth T, Chan H, Chien RN, Liu CJ, et al. Asian‐Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatology International 2012;6:531‐6.
Atkins D, Best D, Briss PA, Eccles M, Falck‐Ytter Y, Flottorp S, et al. GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ (Clinical Research Ed.) 2004;328(7454):1490.
Bani‐Sadr F, Palmer P, Scieux C, Molina JM. Ninety‐six‐week efficacy of combination therapy with lamivudine and tenofovir in patients coinfected with HIV‐1 and wild‐type hepatitis B virus. Clinical Infectious Diseases 2004;39(7):1062‐4.
Bartholomew MM, Jansen RW, Jeffers LJ, Reddy KR, Johnson LC, Bunzendhal H, et al. Hepatitis‐B‐virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997;349(9044):20‐2.
Benaboud S, Pruvost A, Coffie PA, Ekouevi DK, Urien S, Arrive E, et al. Concentrations of tenofovir and emtricitabine in breast milk of HIV‐1‐infected women in Abidjan, Cote d’Ivoire, in the ANRS 12109 TEmAA Study, Step 2. Antimicrobial Agents and Chemotherapy 2011;55:1315‐7.
Benhamou Y, Bochet M, Thibault V, Di Martino V, Caumes E, Bricaire F, et al. Long‐term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus‐infected patients. Hepatology (Baltimore, Md.) 1999;30(5):1302‐6.
Benhamou Y, Fleury H, Trimoulet P, Pellegrin I, Urbinelli R, Katlama C, et al. Anti‐hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV‐infected patients. Hepatology (Baltimore, Md.) 2006;43(3):548‐55.
Benhamou Y. Treating chronic lamivudine‐resistant hepatitis B in HIV co‐infected patients. Gastroenterology Clinics and Biology 2006;30(10):3S22‐5.
Bock CT, Tillmann HL, Torresi J, Klempnauer J, Locarmi S, Manns MP, et al. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology 2002;122(2):264‐73.
Bosch FX, Ribes J, Cleries R, Diaz M. Epidemiology of hepatocellular carcinoma. Clinical Liver Disease 2005;9(2):191‐211.
Brok J, Thorlund K, Gluud C, Wetterslev J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta‐analyses. Journal of Clinical Epidemiology 2008;61(8):763‐9.
Brok J, Thorlund K, Wetterslev J, Gluud C. Apparently conclusive meta‐analyses may be inconclusive – trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently. Conclusive neonatal meta‐analyses. International Journal of Epidemiology 2009;38(1):287‐98.
Bzowej NH. Hepatitis B. Therapy in pregnancy. Current Hepatitis Reports 2010;9:197‐204.
Chen E, Wang L, Lei J, Xu L, Tang H. Meta‐analysis: Adefovir dipivoxil in combination with lamivudine in patients with lamivudine‐resistant hepatitis B virus. Virology Journal 2009;6:163.
Chen Y, Ju T. Comparative meta‐analysis of adefovir dipivoxil monotherapy and combination therapy of adefovir dipivoxil and lamivudine for lamivudine‐resistant chronic hepatitis B. International Journal of Infectious Diseases 2012;16(3):e152‐8.
Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. New England Journal of Medicine 1999;341(1256):1263.
Dienstag JL, Goldin RD, Heathcote EJ, Hann HW, Woessner M, Stephenson SL, et al. Histological outcome during long‐term lamivudine therapy. Gastroenterology 2003;124(1):105‐17.
Dore GJ, Cooper DA, Pozniak AL, DeJesus E, Zhong L, Miller MD, et al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy‐naive and ‐experienced patients coinfected with HIV‐1 and hepatitis B virus. Journal of Infectious Diseases 2004;189(7):1185‐92.
European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. Journal of Hepatology 2012;57:167–85.
Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta‐analysis detected by a simple, graphic test. BMJ (Clinical Research Edition) 1997;315(7109):629‐34.
Fisher A, Musini JV, Bassett K. Antiviral treatments for lamivudine‐resistant chronic hepatitis B adult patients. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD008178]
Fosdick A, Zheng J, Pflanz S, Frey CR, Hesselgesser J, Halcomb RL, et al. Pharmacokinetic and pharmacodynamic properties of GS‐9620, a novel Toll‐like receptor 7 agonist, demonstrate interferon‐stimulated gene induction without detectable serum interferon at low oral doses. Journal of Pharmacology and Experimental Therapeutics 2014;348(1):96‐105.
Gluud C, Nikolova D, Klingenberg SL. Cochrane Hepato‐Biliary Group. About Cochrane (Cochrane Review Groups (CRGs)) 2016, Issue 7. Art. No.: LIVER.
Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, Margolis HS. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. International Journal of Epidemiology 2005;34:1329‐39.
Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Long‐term therapy with adefovir dipivoxil for HBeAg‐negative chronic hepatitis B for up to 5 years. Gastroenterology 2006;131(6):1743‐51.
Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Hoff J, Bani‐Sadr F, Gassin M, Raffi F. Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of anti‐human immunodeficiency virus regimens. Clinical Infectious Diseases 2001;32(6):963‐9.
Hyams KC. Risks of chronicity following acute hepatitis B virus infection: a review. Clinical Infectious Diseases 1995;20:992‐1000.
International Conference on Harmonisation Expert Working Group. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline. Guideline for good clinical practice CFR & ICH Guidelines. Vol. 1, Philadelphia (PA): Barnett International/PAREXEL, 1997.
INC Research. Antiretroviral Pregnancy Registry. www.apregistry.com (accessed prior to 17 August 2016).
Ismail MH, Wiysonge CS, Ricaforte‐Campos JD, Clarke MJ. Entecavir for chronic hepatitis B. Cochrane Database of Systematic Reviews 2014, Issue 7. [DOI: 10.1002/14651858.CD011233]
Jakobsen JC, Wetterslev J, Winkel P, Lange T, Gluud C. Thresholds for statistical and clinical significance in systematic reviews with meta‐analytic methods. BMC Medical Research Methodology 2014;14:120.
Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, et al. Rotterdam Foundation for Liver Resarch. Pegylated interferon alfa‐2b alone or in combination with lamivudine for HBeAg‐positive chronic hepatitis B: a randomized trial. Lancet 2005;365(9454):123‐9.
Kapke GE, Watson G, Sheffler S, Hunt D, Frederick C. Comparison of the Chiron Quantiplex branched DNA (bDNA) assay and the Abbott Genostics solution hybridization assay for quantification of hepatitis B viral DNA. Journal of Viral Hepatitis 1997;4(1):67‐75.
Katz LH, Fraser A, Leibovici L, Tur‐Kaspa R. Lamivudine for preventing reactivation of hepatitis B infection in patients planned to undergo immunosuppressive therapy. Cochrane Database of Systematic Reviews 2009, Issue 2. [DOI: 10.1002/14651858.CD005264.pub2]
Katz LH, Tur‐Kaspa R, Guy DG, Paul M. Lamivudine or adefovir dipivoxil alone or combined with immunoglobulin for preventing hepatitis B recurrence after liver transplantation. Cochrane Database of Systematic Reviews 2010, Issue 7. [DOI: 10.1002/14651858.CD006005.pub2]
Kiyosawa K, Tanaka E. Strategy for lamivudine‐resistant YMDD mutant‐associated chronic hepatitis B. Journal of Gastroenterology 2001;36(2):139‐41.
Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta‐analyses. Annals of Internal Medicine 2001;135(11):982‐9.
Kozłowska J, Jabłońska J, Wiercińska‐Drapało A. Toll‐like receptors in viral hepatitis. Postepy Higieny i Medycyny Doswiadczalnej 2009;21(63):351‐4.
Kuo A, Dienstag JL, Chung RT. Tenofovir disoproxil fumarate for the treatment of lamivudine‐resistant hepatitis B. Clinical Gastroenterology and Hepatology 2004;2(3):266‐72.
Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, et al. A one‐year trial of lamivudine for chronic hepatitis. New England Journal of Medicine 1998;339:61‐8.
Lanford RE, Guerra B, Chavez D, Giavedoni L, Hodara VL, Brasky KM, et al. GS‐9620, an oral agonist of Toll‐like receptor‐7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees. Gastroenterology 2013;144(7):1508‐17.
Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon Alfa‐2a, lamivudine,and the combination for HBeAg‐positive chronic hepatitis B. New England Journal of Medicine 2005;352(26):2682‐95.
Lee WM. Hepatitis B virus infection. New England Journal of Medicine 1997;337:1733‐45.
Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology (Baltimore, Md.) 2001;33(6):1527‐32.
Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology (Baltimore, Md.) 1999;30(2):567‐72.
Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000;119:172‐80.
Liaw Y. Rescue therapy for lamivudine‐resistant chronic hepatitis B: when and how?. Hepatology (Baltimore, Md.) 2007;45(2):266‐8.
Lim SG, Ng TM, Kung N, Krastev Z, Volfova M, Husa P, et al. A double‐blind placebo‐controlled study of emtricitabine in chronic hepatitis B. Archives of Internal Medicine 2006;166(1):49‐56.
Lok A, McMahon B. American Academy for the study of Liver Diseases (AASLD) Practice Guidelines: chronic hepatitis B. Hepatology (Baltimore, Md.) 2009;50(3):1‐35.
Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews 2012, Issue 12. [DOI: 10.1002/14651858.MR000033.pub2]
Mason A, Wick M, White H, Perrillo R. Hepatitis B virus replication in diverse cell types during chronic hepatitis B virus infection. Hepatology (Baltimore, Md.) 1993;18:781‐9.
McMahon BJ. Epidemiology and natural history of hepatitis B. Seminar in Liver Disease 2005;Suppl 1(25):3‐8.
Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomized trials affect estimates of intervention efficacy reported in meta‐analyses? . Lancet 1998;352(9128):609‐13.
Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA statement. BMJ (Clinical Research Ed.) 2009;339:B2535.
Mok S, Mohan S, Hunter KM, Wang YR, Judge TA. Adefovir dipivoxil for adults with lamivudine‐resistant chronic hepatitis B virus infection. Cochrane Database of Systematic Reviews 2015, Issue 12. [DOI: 10.1002/14651858.CD011981]
Mok S, Mohan S, Hunter KM, Wang YR, Judge TA. Interferon for people with lamivudine‐resistant chronic hepatitis B virus infection. Cochrane Database of Systematic Reviews 2016, Issue 4. [DOI: 10.1002/14651858.CD012138]
Mok S, Mohan S, Hunter KM, Wang YR, Judge TA. Telbivudine for adults with lamivudine‐resistant chronic hepatitis B virus infection. Cochrane Database of Systematic Reviews2017 (in press).
Mok S, Mohan S, Hunter KM, Wang YR, Judge TA. Entecavir for patients with lamivudine‐resistant chronic hepatitis B virus infection. Cochrane Database of Systematic Reviews 2017, Issue 1. [DOI: 10.1002/14651858.CD012495]
Mumtaz K, Subhan A, Hamid S, Jafri W. Lamivudine for chronic hepatitis B in adults. Cochrane Database of Systematic Reviews 2007, Issue 2. [DOI: 10.1002/14651858.CD006547]
Mumtaz K, Hamid S, Brok J, Jafri W. Pegylated interferon for chronic hepatitis B. Cochrane Database of Systematic Reviews 2007, Issue 1. [DOI: 10.1002/14651858.CD006303]
Mumtaz K, Ahmed US, Zuberi NF, Salamat S, Jafri W. Lamivudine during pregnancy for preventing hepatitis B virus infection in newborns. Cochrane Database of Systematic Reviews 2010, Issue 9. [DOI: 10.1002/14651858.CD008718]
Njei B, Kumar S, Kongnyuy EJ. Adefovir dipivoxil for chronic hepatitis B. Cochrane Database of Systematic Reviews 2011, Issue 12. [DOI: 10.1002/14651858.CD009521]
Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, McDade H. Viral dynamics in hepatitis B virus infection. Proceedings of the National Academy of Sciences of the United States of America 1996;93:4398‐402.
Peters MG, Andersen J, Lynch P, Liu T, Alston‐Smith B, Brosgart CL, et al. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology (Baltimore, Md.) 2006;44(5):1110‐6.
Petersen J, Dandri M, Mier W, Lütgehetmann M, Volz T, von Weizsäcker F, et al. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nature Biotechnology 2008;26(3):335‐41.
Piroth L, Pol S, Lacombe K, Miailhes P, Rami A, Rey D, et al. Management and treatment of chronic hepatitis B virus infection in HIV positive and negative patients: the EPIB 2008 study. Journal of Hepatology 2010;53(6):1006‐12.
Reijnders JG, Deterding K, Petersen J, Zoulim F, Santantonio T, Buti M, et al. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues. Journal of Hepatology 2010;52:493‐500.
Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Ristig MB, Crippin J, Aberg JA, Powderly WG, Lisker‐Melman M, Kessels L, et al. Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus‐coinfected individuals for whom interferon‐alpha and lamivudine therapy have failed. Journal of Infectious Diseases 2002;186(12):1844‐7.
Rockstroh JK, Bhagani S, Benhamou Y, Bruno R, Mauss S, Peters L, et al. European AIDS Clinical Society (EACS) guidelines for the clinical manage‐ment and treatment of chronic hepatitis B and C coinfection in HIV‐infected adults. HIV Medicine 2008;9:82‐8.
Royle P, Milne R. Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches. International Journal of Technology Assessment in Health Care 2003;19(4):591‐603.
Rücker G, Schwarzer G, Carpenter J. Arcsine test for publication bias in meta‐analyses with binary outcomes. Statistics in Medicine 2008;27:746‐63.
Saldanha J, Gerlich W, Lelie N, Dawson P, Heermann K, Heath A, et al. An international collaborative study to establish a World Health Organization international standard for hepatitis B virus DNA nucleic acid amplification techniques. Vox Sanguinis 2001;80(1):63‐71.
Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine 2012;157(6):429‐38.
Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Health Technology Assessment 2012;16(35):1‐82.
Schalm SW, Heathcote J, Cianciara J, Farrell G, Sherman M, Willems B, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000;46(4):562‐8.
Schultz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408‐12.
Seeger C, Mason WS. Hepatitis B Virus Biology. Microbiology and Molecular Biology Reviews : MMBR 2000;64(1):51‐68.
Sheng YJ, Liu JY, Tong SW, Hu HD, Zhang DZ, Hu P, et al. Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine‐resistant chronic hepatitis B: a systematic review and meta‐analysis. Virology Journal 2011;8:393.
Shey MS, Kongnyuy EJ, Alobwede SM, Wiysonge CS. Co‐formulated abacavir‐lamivudine‐zidovudine for initial treatment of HIV infection and AIDS. Cochrane Database of Systematic Reviews 2013, Issue 3. [DOI: 10.1002/14651858.CD005481.pub3]
Siegfried N, van Deventer PJU, Mahomed FA, Rutherford GW. Stavudine, lamivudine and nevirapine combination therapy for treatment of HIV infection and AIDS in adults. Cochrane Database of Systematic Reviews 2006, Issue 2. [DOI: 10.1002/14651858.CD004535.pub2]
Stuyver LJ, Locarnini SA, Lok A, Richman DD, Carman WF, Dienstag JL, et al. Nomenclature for antiviral‐resistant human hepatitis B virus mutations in the polymerase region. Hepatology (Baltimore, Md.) 2001;33(3):751‐7.
Tan Y, Ding K, Su J, Trinh X, Peng Z, Gong Y, et al. The naturally occurring YMDD mutation among patients chronically infected HBV and untreated with lamivudine: a systematic review and meta‐analysis. PLoS One 2012;7(3):e32789.
Tang H, Chen E, Wang L, Lei J, Xu L. Meta‐analysis: adefovir dipivoxil in combination with lamivudine in patients with lamivudine‐resistant hepatitis B virus. Hepatology (Baltimore, Md.) 2009;50:495A.
Teperman L, Spivey J, Poordad F, Schiano T, Bzowej N, Pungpapong S, et al. Emtricitabine/tenofovir DF combination +/HBIG post‐orthotopic liver transplantation to prevent hepatitis B recurrence in patients with normal to moderate renal impairment: interim results. Journal of Hepatology 2010;52:512‐3.
Terrault N, Roche B, Samuel D. Management of the hepatitis B virus in the liver transplantation setting: a European and an American perspective. Liver Transplantation 2005;11:7716‐32.
Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Mudar MH, et al. AASLD Guidelines for Treatment of Chronic Hepatitis B. Hepatology (Baltimore, Md.) 2016;63(1):261‐83. [DOI: 10.1002/hep.28156]
Thorlund K, Dewvereaux PJ, Wetterslev J, Guyatt G, Ioannidis JP, Thabane L, et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta‐analyses?. International Journal of Epidemiology 2009;38(1):276‐86.
Thorlund K, Anema A, Mills E. Interpreting meta‐analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV‐infected individuals. Clinical Epidemiology 2010;2:57‐66.
Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C. User manual for Trial Sequential Analysis (TSA). ctu.dk/tsa/files/tsa_manual.pdf (accessed 5 November 2016).
Thorlund K, Imberger G, Walsh M, Chu R, Gluud C, Wetterslev J, et al. The number of patients and events required to limit the risk of overestimation of intervention effects in meta‐analysis ‐ a simulation study. PLoS One 2011;6(10):e25491.
Copenhagen Trial Unit. TSA ‐ Trial Sequential Analysis. Version 0.9 Beta. Copenhagen: Copenhagen Trial Unit, 2011.
Tuma P, Medrano J, Resino S, Vispo E, Madejon A, Sanchez‐Piedra C, et al. Incidence of liver cirrhosis in HIV‐infected patients with chronic hepatitis Bor C in the era of highly active antiretroviral therapy. Antiviral Therapy 2010;15(6):881‐6.
van Bömmel F, Wünsche T, Mauss S, Reinke P, Bergk A, Schürmann D, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine‐resistant hepatitis B virus infection. Hepatology (Baltimore, Md.) 2004;40(6):1421‐5.
Wang Y, Chen K, Wu Z, Liu Y, Liu S, Zou Z, et al. Immunizations with hepatitis B viral antigens and a TLR7/8 agonist adjuvant induce antigen‐specific immune responses in HBV‐transgenic mice. International Journal of Infectious Diseases 2014;23(29C):31‐6.
Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology 2008;61(1):64‐75.
Wetterslev J, Thorlund K, Brok J, Gluud C. Estimating required information size by quantifying diversity in random effects model meta‐analyses. BMC Medical Research Methodology 2009;9:86.
World Health Organization. Fact sheet N°204 – Hepatitis B. www.who.int/mediacentre/factsheets/fs204/en/ (accessed 23 March 2015).
Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman DG, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta‐epidemiological study. BMJ (Clinical Research Ed) 2008;336(7644):601‐5.
Yang L, Shi LP, Chen HJ, Tong XK, Wang GF, Zhang YM, et al. Isothiafludine, a novel non‐nucleoside compound, inhibits hepatitis B virus replication through blocking pregenomic RNA encapsidation. Acta Pharmacologica Sinica 2014;35(3):410‐8.
Zhao S, Tang L, Fan X, Chen L. Telbivudine for chronic hepatitis B. Cochrane Database of Systematic Reviews 2010, Issue 9. [DOI: 10.1002/14651858.CD008715]
Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 2009;137:1593‐608.
